Drugs / Cefoxitin
Cefoxitin
also known as
CEFOXITIN SODIUM · Cefoxitin sodium salt · Cefoxitina · Cefoxitine · Cenomycin · J01DC01 · Mefoxin · Mefoxitin · +1 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | MEFOXIN | — | 1995-02-28 – 1996-07-30 | fda.gov ↗ |
| Approved | US (FDA) | MEFOXIN | — | 1978-10-18 | fda.gov ↗ |
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06860802 | Feb 2025 → Jun 2026 overdue | appendicitis | University of Michigan | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07485010 | Apr 2027 → Apr 2031 expected | pulmonary non-tuberculous mycobacterial infection | The University of Queensland | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04310930 | Mar 2020 → Jun 2029 expected | pulmonary non-tuberculous mycobacterial infection | The University of Queensland | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05755789 | Jun 2023 → May 2025 | — | Poitiers University Hospital | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02474706 | Mar 2016 → Dec 2017 | urinary tract infection | Central Hospital, Nancy, France | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02703857 | Feb → Sep 2016 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase not applicable3 trials · 1 met primary | ||||||
| — | NCT02958059 | Dec 2016 → Aug 2020 | ampulla of vater cancer, choledocholithiasis, hilar cholangiocarcinoma | Yonsei University | Unknown | Met primary |
| — | NCT01820793 | May 2013 → Jul 2015 | acute pyelonephritis | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| — | NCT00343317 | Feb 2003 → May 2005 | puerperal infection | University of KwaZulu | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03960970 Background | Sep 2019 | endometritis, skin infection | RWJ Barnabas Health at Jersey City Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03269994 Comparator | Nov 2017 → Jan 2025 | malignant pancreatic neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT07043855 Comparator | May 2026 → Oct 2028 expected | infectious disease | Asan Medical Center | Enrolling by invitation | No outcome recorded |
| — | NCT02800785 Comparator | May 2016 → Mar 2020 | appendicitis | University of Washington | Completed | No outcome recorded |
| — | NCT02985086 Comparator | Jul 2013 → Jul 2018 | — | Hospital de Santa Maria, Portugal | Unknown | No outcome recorded |
| — | NCT00186082 Comparator | Sep 2003 → Jun 2006 | puerperal infection | Stanford University | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cefoxitin | “a preoperative second-generation cephalosporin (cefoxitin) followed by postoperative cefotaxime plus metronidazole for 3 days” NCT07043855 ↗ |
| Known as | CEFOXITIN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL996 ↗ |
| Known as | Cefoxitin sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL996 ↗ |
| Known as | Cefoxitina | ChEMBL registry synonym — accepted as the source's own label CHEMBL996 ↗ |
| Known as | Cefoxitine | ChEMBL registry synonym — accepted as the source's own label CHEMBL996 ↗ |
| Known as | Cenomycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL996 ↗ |
| Known as | J01DC01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL996 ↗ |
| Known as | Mefoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03960970 ↗ |
| Known as | Mefoxitin | ChEMBL registry synonym — accepted as the source's own label CHEMBL996 ↗ |
| Known as | Pacetin | “Pacetin® (cefoxitin)” NCT02958059 ↗ |
| Action | Inhibit | “which interferes with the action of the extended-spectrum β-lactamase and renders it ineffective against cephamycins.” NCT01820793 ↗ |
| Modality | Small molecule | “Cefoxitin (2nd generation cephalosporin)” NCT02958059 ↗ |
| Route | Intravenous | “1 g intravenously” NCT00186082 ↗ |